Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - Ασθμα - Φάρμακα αποφρακτικών παθήσεων των αναπνευστικών οδών, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).